Stipple Bio raises $100M
Stipple Bio announced a Series A round of $100M on 6 April 2026. The company operates in HealthTech and is based in United States. It was founded by Jeff Landau, CEO.
Founder
Jeff Landau
CEO, Stipple Bio
Outreach angles
- -Jeff Landau joined Stipple Bio alongside cancer biology pioneers Dr. Aaron Ring (Fred Hutch) and Dr. Aashish Manglik (UCSF), building a world-class scientific founding team before emerging from stealth.
- -Landau has a track record in clinical-stage biotech leadership, guiding companies through IND filings and early-stage clinical trial design.
- -Stipple Bio's oversubscribed $100M Series A, co-led by a16z Bio+Health and RA Capital, funds the advancement of STP-100, a novel antibody-drug conjugate, into early clinical trials in 2027.
Signals
Series AHealthcareDeep TechRegulated IndustryHiring
Round details
Company: Stipple Bio
Domain: stipple.bio
Amount: $100M
Stage: Series A
Industry: HealthTech
Country: United States
Announced: 6 April 2026
Other HealthTech raises
Recently funded in United States